Cannabis
Filing of Aphria Inc.’s Form 40-F with the U.S. Securities and Exchange Commission
On August 1, 2019, Aphria Inc. (“Aphria” or the “Company”) (TSX: APHA and NYSE: APHA) filed its annual report for the fiscal year ended May 31, 2019 on Form 40-F (as amended, the “2019 Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”).
The 2019 Annual Report contains audited financial statements, management’s discussion and analysis and other disclosures. Printed copies of the Company’s fiscal 2019 annual financial statements are available free of charge to Aphria Inc. shareholders upon written request to [email protected].
The 2019 Annual Report can be accessed by visiting the SEC’s website (www.sec.gov) and Aphria’s website (https://aphriainc.com/investors/)
SOURCE Aphria Inc.
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
Cannabis
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE2 weeks ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis6 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis5 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan4 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey